Furthermore, it has been shown that effective targeted therapies against EGFR depend on the KRAS and BRAF status in patients with metastatic CRC and lung cancer, indicating that mutations could influence the activation of the EGFR pathway [18]. Here, EGFR is linked to lung carcinoma.